

Department of Psychiatry, Université de Montréal, Montreal, Quebec, Canada.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 02/2007; 297(4):367-79. DOI: 10.1001/jama.297.4.367
Source: PubMed

ABSTRACT Few randomized controlled trials have evaluated the efficacy of treatments for major depression in patients with coronary artery disease (CAD). None have simultaneously evaluated an antidepressant and short-term psychotherapy.
To document the short-term efficacy of a selective serotonin reuptake inhibitor (citalopram) and interpersonal psychotherapy (IPT) in reducing depressive symptoms in patients with CAD and major depression.
The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy, a randomized, controlled, 12-week, parallel-group, 2 x 2 factorial trial conducted May 1, 2002, to March 20, 2006, among 284 patients with CAD from 9 Canadian academic centers. All patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for diagnosis of major depression of 4 weeks' duration or longer and had baseline 24-item Hamilton Depression Rating Scale (HAM-D) scores of 20 or higher.
Participants underwent 2 separate randomizations: (1) to receive 12 weekly sessions of IPT plus clinical management (n = 142) or clinical management only (n = 142) and (2) to receive 12 weeks of citalopram, 20 to 40 mg/d (n = 142), or matching placebo (n = 142).
The primary outcome measure was change between baseline and 12 weeks on the 24-item HAM-D, administered blindly during centralized telephone interviews (tested at alpha = .033); the secondary outcome measure was self-reported Beck Depression Inventory II (BDI-II) score (tested at alpha = .017).
Citalopram was superior to placebo in reducing 12-week HAM-D scores (mean difference, 3.3 points; 96.7% confidence interval [CI], 0.80-5.85; P = .005), with a small to medium effect size of 0.33. Mean HAM-D response (52.8% vs 40.1%; P = .03) and remission rates (35.9% vs 22.5%; P = .01) and the reduction in BDI-II scores (difference, 3.6 points; 98.3% CI, 0.58-6.64; P = .005; effect size = 0.33) also favored citalopram. There was no evidence of a benefit of IPT over clinical management, with the mean HAM-D difference favoring clinical management (-2.26 points; 96.7% CI, -4.78 to 0.27; P = .06; effect size, 0.23). The difference on the BDI-II did not favor clinical management (1.13 points; 98.3% CI, -1.90 to 4.16; P = .37; effect size = 0.11).
This trial documents the efficacy of citalopram administered in conjunction with weekly clinical management for major depression among patients with CAD and found no evidence of added value of IPT over clinical management. Based on these results and those of previous trials, citalopram or sertraline plus clinical management should be considered as a first-step treatment for patients with CAD and major depression. Identifier: ISRCTN15858091.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The elderly patients with coronary heart disease (CHD) are often accompanied with depression. This study aimed to assess the effect of St. John's wort extract (SWE) on depressive disorder in elderly patients with unstable angina pectoris.
    World journal of emergency medicine. 01/2010; 1(1):41-4.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Cardiovascular diseases (CVDs) are commonly comorbid with depression and vice versa. Polyunsaturated fatty acids (PUFAs) have been suggested to mediate in CVDs and depression in cross-sectional and observational studies. With the patients of CVDs, we investigated the role of depression on the effect of PUFAs. Methods: Forty-four patients with CVDs were recruited and assessed with Hamilton depression rating scale (HAMD). Patients’ CVDs markers were measured by electrocardiogram and their red blood cell (RBC) samples were collected for PUFAs analyses. Results: The data of 44 subjects were analyzed; where 10 participants (23%) with CVDs had moderate or severe depression, defined by a HAMD score more than 19 points. The moderate depression group had lower docosahexaenoic acid (DHA), omega-3 (N3) and omega-6(N6) to N3 (N6/N3) ratio than non-depression group (HAMD score less than 8), while no differences between the 2 groups in terms of corrected QT (QTc) intervals and high sensitivity C-reactive protein (hsCRP) levels. Furthermore, when we analyzed the data with an inclusion of a more heterogeneous depression group, where HAMD score is greater than or equal to 10 (mild depression group, N = 24), the differences in PUFAs levels between the 2 groups disappear. Secondary analysis of the moderate depression group showed a positive correlation between DHA, N3 PUFAs, and N6/N3 ratio and total HAMD scores, a positive correlation between N3 PUFAs and QTc intervals in non-depression group. Conclusion: Moderate depression group of patients with CVDs had lower levels of DHA, N3, and N6/N3 ratio than non-depression group, while both groups had no differences in QTc and hsCRP. On the other hand, the differences in PUFAs levels disappear in the mild depression group after inclusion of patients with CVDs with greater heterogeneity of depression. Hence, the role of N3 PUFAs is implicated in depression of patients with CVDs if the depression status is more strictly defined.
    Brain Behavior and Immunity 11/2014; · 5.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eine depressive Episode wird nach den modernen Klassifikationssystemen anhand definierter Symptome diagnostiziert. Nach einer großen Metaanalyse liegt die Prävalenz einer klinisch bedeutsamen Depression bei chronischer Herzinsuffizienz über 20%. Ätiologisch bedeutsam sind sowohl individuelle (genetische) Disposition und soziales Umfeld als auch aus der Herzinsuffizienz resultierende Belastungs- und Risikofaktoren. Wie bei der koronaren Herzkrankheit stellt auch bei Herzinsuffizienz die Depression einen prognostischen Faktor dar, der das Mortalitätsrisiko erhöht. Mögliche Mediatoren dieses Zusammenhangs umfassen sowohl biologische (Schweregrad der Herzinsuffizienz, autonome und immunologische Dysregulation, multiple Komorbiditäten) als auch verhaltensbezogene Faktoren (Gesundheitsverhalten, Compliance mit pharmakologischen und nicht-pharmakologischen Therapiemaßnahmen). Sich wechselseitig beeinflussende Pathomechanismen, aber auch eine partiell gemeinsame genetische Disposition werden diskutiert. Wenig aufwändige Screeninginstrumente erleichtern in der Praxis die Diagnose. Die Evidenz dafür, dass spezifische Therapiemaßnahmen (Psychotherapie, selektive Serotoninwiederaufnahmehemmer) bei Patienten mit Herzinsuffizienz nicht nur die Depressivität verbessern, sondern auch Morbidität und Mortalität günstig beeinflussen, fehlt allerdings bisher.
    Der Internist 01/2008; 49(4). · 0.33 Impact Factor

Full-text (3 Sources)

Available from
May 31, 2014